ReLIA Bioengineering
Shenzhen, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Chinese diagnostics company developing rapid POCT solutions for infectious diseases using chemiluminescence and fluorescent technologies.
Infectious DiseaseImmunology
Technology Platform
Point-of-care testing (POCT) platforms using chemiluminescence and fluorescent detection technologies for rapid diagnostic results.
Opportunities
Expansion into broader infectious disease panels beyond COVID-19, leveraging POCT trend toward decentralized testing, and potential international market growth through their export-certified products.
Risk Factors
High dependence on infectious disease testing market, intense competition in POCT diagnostics, and regulatory challenges in international markets.
Competitive Landscape
Competes with global POCT companies like Abbott (BinaxNOW), Quidel, and Roche, as well as Chinese diagnostics firms; differentiation through chemiluminescence technology and dual U.S.-China R&D structure.